Animal models for the negative symptoms of schizophrenia

被引:155
作者
Ellenbroek, BA [1 ]
Cools, AR [1 ]
机构
[1] Univ Nijmegen, Dept Psychoneuropharmacol, NL-6500 HB Nijmegen, Netherlands
来源
BEHAVIOURAL PHARMACOLOGY | 2000年 / 11卷 / 3-4期
关键词
schizophrenia; negative symptoms; positive symptoms; animal models;
D O I
10.1097/00008877-200006000-00006
中图分类号
B84 [心理学]; C [社会科学总论]; Q98 [人类学];
学科分类号
03 ; 0303 ; 030303 ; 04 ; 0402 ;
摘要
Negative or defect symptoms refer to a reduction in normal functioning. In schizophrenia, negative symptoms encompass, among others, anhedonia, flat affect, avolition and social withdrawal. These symptoms have been found to be particularly prominent in the more chronic phase of the illness and seem to be virtually insensitive to current antipsychotic treatment. This review focuses on the possibilities and limitations of animal models for the negative symptoms of schizophrenia. Following a review of the negative symptoms in schizophrenia, attention is focused on the two symptoms most often modelled in animals - anhedonia and social withdrawal. We then look at the important question of how to model schizophrenic pathology in animals. Since the exact pathology is still far from clear, most efforts have in the past concentrated on using psychotomimetic drugs such as amphetamine or phencyclidine. The recently accumulated knowledge that schizophrenia probably results from disturbances in the normal development of the brain has led to a surge of new animal models in which the long-term consequences of early manipulations are investigated. However, so far these models have predominantly concentrated on the positive rather than the negative symptoms of schizophrenia. The last part of this review is dedicated to the question of validation of animal models for anhedonia and social withdrawal. The general conclusion is that very few models have so far been adequately tested. The lack of currently effective treatment further hampers the study of such validation. (C) 2000 Lippincott Williams & Wilkins.
引用
收藏
页码:223 / 233
页数:11
相关论文
共 108 条
[1]  
ANDREASEN NC, 1982, ARCH GEN PSYCHIAT, V39, P789
[2]   PARTIAL IMPROVEMENT IN NEGATIVE SCHIZOPHRENIC SYMPTOMS AFTER AMPHETAMINE [J].
ANGRIST, B ;
PESELOW, E ;
RUBINSTEIN, M ;
CORWIN, J ;
ROTROSEN, J .
PSYCHOPHARMACOLOGY, 1982, 78 (02) :128-130
[3]   AMPHETAMINE PSYCHOSIS - BEHAVIORAL AND BIOCHEMICAL ASPECTS [J].
ANGRIST, B ;
SATHANANTHAN, G ;
WILK, S ;
GERSHON, S .
JOURNAL OF PSYCHIATRIC RESEARCH, 1974, 11 :13-23
[4]  
Angrist B, 1994, Amphetamine and Its Analogues, P387
[5]   ANTAGONISM OF PHENCYCLIDINE-INDUCED DEFICITS IN PREPULSE INHIBITION BY THE PUTATIVE ATYPICAL ANTIPSYCHOTIC OLANZAPINE [J].
BAKSHI, VP ;
GEYER, MA .
PSYCHOPHARMACOLOGY, 1995, 122 (02) :198-201
[6]   Social behaviour in rats lesioned with ibotenic acid in the hippocampus:: quantitative and qualitative analysis [J].
Becker, A ;
Grecksch, G ;
Bernstein, HG ;
Höllt, V ;
Bogerts, B .
PSYCHOPHARMACOLOGY, 1999, 144 (04) :333-338
[7]   AN ANALYSIS OF SOCIAL COMPETENCE IN SCHIZOPHRENIA [J].
BELLACK, AS ;
MORRISON, RL ;
WIXTED, JT ;
MUESER, KT .
BRITISH JOURNAL OF PSYCHIATRY, 1990, 156 :809-818
[8]  
BODI TIBOR, 1959, ANTIBIOT MED AND CLIN THER, V6, P79
[9]  
BORSINI F, 1985, INT J OBESITY, V9, P277
[10]  
BOZARTH MA, 1991, MESOLIMBIC DOPAMINE SYSTEM : FROM MOTIVATION TO ACTION, P301